| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Barbara Davis Center for Childhood Diabetes/University of Colorado Health Sciences Center, Denver, CO 80262; and
Laboratory of Public Health, Virology/Serology Branch, North Carolina State, Raleigh, NC 27611
Pretreatment of pancreatic islets in 95% oxygen culture depletes graft-associated APCs and leads to indefinite allograft acceptance in immunocompetent recipients. As such, the APC-depleted allograft represents a model of peripheral alloantigen presentation in the absence of donor-derived costimulation. Over time, a state of donor-specific tolerance develops in which recipients are resistant to donor APC-induced graft rejection. Thus, persistence of the graft is sufficient to induce tolerance independent of other immune interventions. Donor-specific tolerance could be adoptively transferred to immune-deficient SCID recipient mice transplanted with fresh immunogenic islet allografts, indicating that the original recipient was not simply "ignorant" of donor antigens. Interestingly, despite the fact that the original islet allograft presented only MHC class I alloantigens, CD8+ T cells obtained from tolerant animals readily collaborated with naive CD4+ T cells to reject donor-type islet grafts. Conversely, tolerant CD4+ T cells failed to collaborate effectively with naive CD8+ T cells for the rejection of donor-type grafts. In conclusion, the MHC class I+, II- islet allograft paradoxically leads to a change in the donor-reactive CD4 T cell subset and not in the CD8 subset. We hypothesize that the tolerant state is not due to direct class I alloantigen presentation to CD8 T cells but, rather, occurs via the indirect pathway of donor Ag presentation to CD4 T cells in the context of host MHC class II molecules.
This article has been cited by other articles:
|
|
 |
|
  L. Makhlouf, A. Yamada, T. Ito, R. Abdi, M. J. I. Ansari, C. Q. Khuong, H. J. Winn, H. Auchincloss Jr., and M. H. Sayegh Allorecognition and Effector Pathways of Islet Allograft Rejection in Normal versus Nonobese Diabetic Mice J. Am. Soc. Nephrol., August 1, 2003; 14(8): 2168 - 2175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. R. Rayat, Z. A. Johnson, J. N. Beilke, G. S. Korbutt, R. V. Rajotte, and R. G. Gill The Degree of Phylogenetic Disparity of Islet Grafts Dictates the Reliance on Indirect CD4 T-Cell Antigen Recognition for Rejection Diabetes, June 1, 2003; 52(6): 1433 - 1440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. E. Phillips, T. G. Markees, J. P. Mordes, D. L. Greiner, and A. A. Rossini Blockade of CD40-Mediated Signaling Is Sufficient for Inducing Islet But Not Skin Transplantation Tolerance J. Immunol., March 15, 2003; 170(6): 3015 - 3023. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Pimenta-Araujo, L. Mascarell, M. Huesca, A. Cumano, and A. Bandeira Embryonic Thymic Epithelium Naturally Devoid of APCs Is Acutely Rejected in the Absence of Indirect Recognition J. Immunol., November 1, 2001; 167(9): 5034 - 5041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Diamond and R. G. Gill An Essential Contribution by IFN-{gamma} to CD8+ T Cell-Mediated Rejection of Pancreatic Islet Allografts J. Immunol., July 1, 2000; 165(1): 247 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Nicolls, M. Coulombe, H. Yang, A. Bolwerk, and R. G. Gill Anti-LFA-1 Therapy Induces Long-Term Islet Allograft Acceptance in the Absence of IFN-{gamma} or IL-4 J. Immunol., April 1, 2000; 164(7): 3627 - 3634. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
